Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib Plus Trametinib in Metastatic MET Exon 14 Skipping Mutation Positive NSCLC
NCT05435846Phase 1Terminated
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of capmatinib and trametinib in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoints: Proportion of participants with reported dose limiting toxicity and Proportion of participants with treatment-emergent adverse events up to 12 months. Started Aug 2022; status: terminated.
02
Drugs
capmatinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05435846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435846.